Chemomab Therapeutics Ltd. Annual Income Tax Expense (Benefit) in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Chemomab Therapeutics Ltd. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2018 to 2024.
  • Chemomab Therapeutics Ltd. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000, a 100% decline year-over-year.
  • Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2024 was $0.000.
  • Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2023 was $0.000.
  • Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2022 was -$534K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $0 $0 Jan 1, 2024 Dec 31, 2024 20-F 2025-04-04
2023 $0 +$534K Jan 1, 2023 Dec 31, 2023 20-F 2025-04-04
2022 -$534K -$534K Jan 1, 2022 Dec 31, 2022 20-F 2025-04-04
2021 $0 $0 Jan 1, 2021 Dec 31, 2021 20-F 2024-03-28
2020 $0 $0 Jan 1, 2020 Dec 31, 2020 10-K 2021-03-09
2019 $0 -$306K -100% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 $306K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.